Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG)
Agnieszka Pluta, Agnieszka Wierzbowska(Medical University of Lodz), Ewa Wawrzyniak(Medical University of Lodz), Karol Wójcik, Krzysztof Warzocha(Instytut Hematologii i Transfuzjologi), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Agnieszka Piekarska(Gdańsk Medical University), Ewa Bodzenta, Tomasz Wróbel, Magdalena Czemerska(Medical University of Lodz), Marek Hus(Medical University of Lublin), Marta Sobas, Olga Grzybowska‐Izydorczyk, Sebastian Giebel(The Maria Sklodowska-Curie National Research Institute of Oncology), Konrad Stępka(Medical University of Lodz), Łukasz Bołkuń(Medical University of Białystok), Janusz Kłoczko(University Clinical Hospital In Bialystok), Grzegorz Helbig(Medical University of Silesia), Sebastian Grosicki(Medical University of Silesia), Elżbieta Patkowska(Institute for Transfusion Medicine), Kamil Brzozowski(Medical University of Lodz), Anna Szmigielska‐Kapłon(Medical University of Lodz), Marta Kuydowicz(Medical University of Lodz), Małgorzata Raźny, Tomasz Gromek(Medical University of Lublin), Jerzy Hołowiecki(Medical University of Silesia), Wanda Knopińska‐Posłuszny, Tadeusz Robak(Medical University of Lodz), Piotr Stelmach(Medical University of Lodz), Andrzej Hellman(Gdańsk Medical University), Anna Krawczyńska(Medical University of Lodz), Mateusz Nowicki(Medical University of Lodz)
Cited by 3
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
|New England Journal of Medicine|2007|1.8k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k